Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

Presentation TCT 2013

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Presenter: Michael Ezekowitz

October 31, 2013

News Conference News TCT 2013

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

October 29, 2013

News Conference News TCT 2013

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

October 28, 2013

News Conference News TCT 2012

Stroke Prevention Strategies Discussed

October 26, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Advertisement

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

Understanding Differences Among New Oral Anticoagulants Should Increase Compliance

Stroke Prevention Strategies Discussed

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content